Thursday’s HotCopper Trends: Mesoblast bags FDA tick, Hot Chili extends mine life | March 27, 2025

The Market Herald03-27

The ASX has been down 0.55% at 7,956 points on Thursday so far.

Energy has been the strongest sector, up 0.75%, followed by Materials, up 0.4%, and Utilities, up 0.25%.

Information Technology has been the worst-performing sector, down 2%, followed by Real Estate, down 1.6%, and Discretionary, down 1%.

Mesoblast (ASX:MSB) has been the most watched stock on HotCopper forums today after the company’s proprietary drug Ryoncil scored approval from the U.S. Food and Drug Administration for use in the United States.

Also trending on the forums is FBR (ASX:FBR), which successfully completed an institutional capital raise of $6.3 million at an issue price of one cent per share.

Rounding out the most discussed today is Hot Chili (ASX:HCH) after the miner revealed the life of its Costa Fuego Copper-Gold Project in Chile has been extended to 20 years. The move follows the completion of a Prefeasibility Study.

More market news

51st State: What is Trump’s endgame with tariffs – and what will it mean for Canada?

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment